ATE243525T1 - Zubereitungen aus immunogenen molekülen, die granulozyten-makrophagen-stimulierenden faktor als adjuvans enthalten - Google Patents

Zubereitungen aus immunogenen molekülen, die granulozyten-makrophagen-stimulierenden faktor als adjuvans enthalten

Info

Publication number
ATE243525T1
ATE243525T1 AT97904876T AT97904876T ATE243525T1 AT E243525 T1 ATE243525 T1 AT E243525T1 AT 97904876 T AT97904876 T AT 97904876T AT 97904876 T AT97904876 T AT 97904876T AT E243525 T1 ATE243525 T1 AT E243525T1
Authority
AT
Austria
Prior art keywords
adjuvant
stimulating factor
macropage
preparations
molecules containing
Prior art date
Application number
AT97904876T
Other languages
English (en)
Inventor
Elke Jager
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE243525T1 publication Critical patent/ATE243525T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97904876T 1996-02-09 1997-01-28 Zubereitungen aus immunogenen molekülen, die granulozyten-makrophagen-stimulierenden faktor als adjuvans enthalten ATE243525T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/598,909 US6096313A (en) 1996-02-09 1996-02-09 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
PCT/US1997/001249 WO1997028816A1 (en) 1996-02-09 1997-01-28 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Publications (1)

Publication Number Publication Date
ATE243525T1 true ATE243525T1 (de) 2003-07-15

Family

ID=24397438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97904876T ATE243525T1 (de) 1996-02-09 1997-01-28 Zubereitungen aus immunogenen molekülen, die granulozyten-makrophagen-stimulierenden faktor als adjuvans enthalten

Country Status (12)

Country Link
US (1) US6096313A (de)
EP (1) EP0932411B1 (de)
JP (1) JP2000506518A (de)
AT (1) ATE243525T1 (de)
AU (1) AU723147B2 (de)
CA (1) CA2244867C (de)
DE (1) DE69723092T2 (de)
DK (1) DK0932411T3 (de)
ES (1) ES2196305T3 (de)
PT (1) PT932411E (de)
WO (1) WO1997028816A1 (de)
ZA (1) ZA97858B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TW581709B (en) 1999-10-22 2004-04-01 Asahi Kasei Corp Heat-resistant microporous film
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
HK1052314A1 (zh) * 2000-08-11 2003-09-11 Favrille, Inc. 改变t细胞介导的病理的方法和组合物
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003301399B2 (en) * 2002-10-18 2006-07-06 Asahi Kasei Medical Co., Ltd. Microporous hydrophilic membrane
ES2633389T3 (es) 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
WO2005049073A2 (en) 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
ES2523172T3 (es) 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
EP1760089B1 (de) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB2432721B (en) * 2005-11-25 2011-06-22 Seiko Epson Corp Electrochemical cell structure and method of fabrication
GB2432722A (en) * 2005-11-25 2007-05-30 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432723B (en) * 2005-11-25 2010-12-08 Seiko Epson Corp Electrochemical cell and method of manufacture
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3320912B1 (de) 2008-04-17 2021-03-31 IO BIOTECH ApS Auf indolamin-2,3-dioxygenase basierende immuntherapie
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP4079319A1 (de) 2011-10-17 2022-10-26 IO Biotech ApS Pd-l1 immuntherapie
WO2013060328A1 (en) 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
EP2606897A1 (de) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Zusammensetzungen für die Behandlung von Krankheiten, die von eingehüllten Viren verursacht werden
EP2617434A1 (de) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
EP2703482A1 (de) 2012-09-04 2014-03-05 Laboratorios Del. Dr. Esteve, S.A. VSV-HIV-Virenpartikel mit Mangel an Umkehrtranskriptasefunktionalität und therapeutische Anwendungen davon
ES2639855T3 (es) 2013-12-23 2017-10-30 Exchange Imaging Technologies Gmbh Nanopartícula conjugada a péptidos de unión a CD44
SI3193917T1 (sl) 2014-09-17 2022-02-28 Io Biotech Aps Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
EP3147364A1 (de) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antivirale wirkstoffe mit einem oligonukleotid-lipid-konjugat-bildenden g-quadruplex
EP3468585A2 (de) 2016-06-10 2019-04-17 IO Biotech APS Calr- und jak2-impfstoffzusammensetzungen
EP3275462A1 (de) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virusähnliche partikel mit hochdichter beschichtung zur herstellung von neutralisierenden antikörpern
AU2020279988A1 (en) 2019-05-22 2021-12-23 Aelix Therapeutics, S.L. Dosage regimens for vaccines
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4662393A (en) * 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
ATE283069T1 (de) * 1996-08-16 2004-12-15 Univ Johns Hopkins Med Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Also Published As

Publication number Publication date
US6096313A (en) 2000-08-01
EP0932411B1 (de) 2003-06-25
PT932411E (pt) 2003-11-28
JP2000506518A (ja) 2000-05-30
DE69723092D1 (de) 2003-07-31
AU723147B2 (en) 2000-08-17
CA2244867C (en) 2003-09-09
ZA97858B (en) 1997-08-04
DK0932411T3 (da) 2003-08-18
WO1997028816A1 (en) 1997-08-14
ES2196305T3 (es) 2003-12-16
EP0932411A4 (de) 2001-09-26
CA2244867A1 (en) 1997-08-14
EP0932411A1 (de) 1999-08-04
DE69723092T2 (de) 2003-12-18
AU1755297A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
ATE243525T1 (de) Zubereitungen aus immunogenen molekülen, die granulozyten-makrophagen-stimulierenden faktor als adjuvans enthalten
IL78463A0 (en) Phenylnaphthalene derivatives,their preparation and pharmaceutical and cosmetic preparations containing them
NO852872L (no) Fremgangsmaate for fremstilling av nye tetrapyrroler.
DE69532031D1 (de) Schilddrüsenhormone enthaltende mittel
AU629669B2 (en) Diarylacetylenes, the preparations and use thereof
CA2274074A1 (en) Novel compounds with analgesic effect
ATE177640T1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
CA2119636A1 (en) Low pH Aqueous Cosmetic Gel Containing Non-Ionic Polyacrylamide Derivatives
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
ATE188965T1 (de) Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
RU2001109436A (ru) Косметическая композиция
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
AU4926690A (en) Oxidized diphenylheteroalkanes, the preparation and use thereof
AU588562B2 (en) Dopamine-beta-hydroxylase inhibitors
AU617036B2 (en) Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
AU6922891A (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
IT1251497B (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
EP0371733A3 (de) Dopamin-beta-hydroxylase-Inhibitoren
RU94001368A (ru) Гемостимулятор
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
IT1250647B (it) Uso di ammine organiche cicliche in composizioni dermatologiche
ATE66816T1 (de) Zusammensetzung fuer die bereitung eines arzneimittels zur topischen behandlung paradentaler krankheiten.
SE9401596D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0932411

Country of ref document: EP